JHS Svendgaard promoters confirm no share encumbrance in FY26

1 min read     Updated on 01 Jul 2026, 06:38 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

JHS Svendgaard Laboratories Limited disclosed that its promoters and promoter group members did not create any encumbrance on their shares during the financial year 2025-2026. The disclosure was submitted to the stock exchanges under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The confirmation covers four individuals, including Promoter Nikhil Nanda.

powered bylight_fuzz_icon
44413713

*this image is generated using AI for illustrative purposes only.

JHS Svendgaard Laboratories Limited has confirmed that its promoters and members of the promoter group did not encumber any shares held in the company during the financial year 2025-2026. This disclosure, submitted to the stock exchanges, assures investors that the shareholding of the key stakeholders remains free from liens or charges as of March 31, 2026.

The confirmation was provided in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was addressed to the Audit Committee of the company and subsequently communicated to BSE Limited and the National Stock Exchange of India Limited.

The disclosure identifies four individuals falling under the promoter and promoter group categories. The list includes Nikhil Nanda, who signed the disclosure on behalf of the entire group.

Promoter and Promoter Group Details

The following table outlines the names and categories of the promoters as of the record date:

S. No. Name(s) Category
1. Mr. Nikhil Nanda Promoter
2. Mrs. Sushma Nanda Promoter Group
3. Mr. Daljit Singh Grewal Promoter Group
4. Late Sh. Harish Chander Nanda Promoter Group

The statement explicitly notes that no encumbrance was made directly or indirectly on the shares held by these individuals in jhs svendgaard laboratories during the specified financial year.

Historical Stock Returns for JHS Svendgaard Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.28%-2.05%-15.50%-22.30%-42.67%-66.16%

How might this clean shareholding status influence investor confidence and the stock's liquidity in the upcoming quarter?

Does the lack of share encumbrance suggest the promoters are prioritizing long-term holding over raising capital through pledging?

Could this disclosure signal potential plans for corporate actions such as a dividend payout or further equity expansion?

JHS Svendgaard Laboratories
View Company Insights
View All News
like17
dislike

JHS Svendgaard narrows net loss to ₹192.24 lakh in FY26

1 min read     Updated on 30 May 2026, 03:59 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

JHS Svendgaard Laboratories Limited narrowed its net loss to ₹192.24 lakh for FY26 from ₹1,974.43 lakh in the previous year, while revenue from operations increased to ₹10,169.47 lakh. The board approved the audited financial results on May 26, 2026, and the statutory auditors issued an unmodified opinion.

powered bylight_fuzz_icon
40831443

*this image is generated using AI for illustrative purposes only.

JHS Svendgaard Laboratories Limited narrowed its net loss to ₹192.24 lakh for the financial year ended March 31, 2026, from a loss of ₹1,974.43 lakh in the previous year. Revenue from operations for the year rose to ₹10,169.47 lakh, compared to ₹9,199.73 lakh in FY25, while total income stood at ₹10,514.34 lakh. The company's board of directors approved the audited standalone and consolidated financial results at a meeting held on May 26, 2026. The statutory auditors, M/s V.K. Khosla & Co., issued an unmodified opinion on the financial results.

Financial Performance

The company reported a basic and diluted earnings per share (EPS) of (₹0.22) for FY26, an improvement from (₹2.37) in the prior year. For the quarter ended March 31, 2026, the net loss was ₹356.56 lakh, with revenue from operations at ₹3,269.57 lakh. The board also took note of the Auditor’s Report issued by the statutory auditors. The paid-up equity share capital of the company stands at ₹8,740.58 lakh, comprising 8,74,05,767 equity shares of ₹10 each, following the conversion of warrants.

Metric FY26 (₹ in lakh) FY25 (₹ in lakh)
Revenue from Operations 10,169.47 9,199.73
Total Income 10,514.34 9,487.44
Net Profit/(Loss) (192.24) (1,974.43)
Basic EPS (₹) (0.22) (2.37)

Operational and Capital Details

The company utilized funds raised through preferential allotment for projects in Jammu and Kashmir, general corporate purposes, and capital expenditure. Capital advances amounting to ₹3,252.75 lakh for facilities in Himachal Pradesh and ₹1,328.30 lakh for projects in Jammu & Kashmir were considered recoverable by the management. The auditors noted material weaknesses in internal financial controls over financial reporting, specifically regarding the reconciliation of trade receivables and payables, and the identification of non-moving inventory. The meeting was conducted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for JHS Svendgaard Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.28%-2.05%-15.50%-22.30%-42.67%-66.16%

What specific measures will management implement to address the material weaknesses identified in internal financial controls?

How will the capital advances for the Himachal Pradesh and Jammu & Kashmir facilities impact production capacity in the coming fiscal year?

Is the company on track to achieve a net profit in FY27 given the significant reduction in losses year-over-year?

JHS Svendgaard Laboratories
View Company Insights
View All News
like15
dislike

More News on JHS Svendgaard Laboratories

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-42.67%